Diabetes (type 2) - rosiglitazone (replaced by TA63)

Rosiglitazone for type 2 diabetes

Description

This guidance has been replaced by Diabetes (type 2) - glitazones (review).

Guidance documents

• No documents found

Implementing this guidance

• None available

Other information

• Background information

• This guidance is currently being reviewed